These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27631463)

  • 1. Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer.
    Pointreau Y; Azzopardi N; Ternant D; Calais G; Paintaud G
    Ther Drug Monit; 2016 Oct; 38(5):567-72. PubMed ID: 27631463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.
    Azzopardi N; Lecomte T; Ternant D; Boisdron-Celle M; Piller F; Morel A; Gouilleux-Gruart V; Vignault-Desvignes C; Watier H; Gamelin E; Paintaud G
    Clin Cancer Res; 2011 Oct; 17(19):6329-37. PubMed ID: 21953502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
    Song Q; Li X; Li B
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.
    Dirks NL; Nolting A; Kovar A; Meibohm B
    J Clin Pharmacol; 2008 Mar; 48(3):267-78. PubMed ID: 18218786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab.
    Ye AY; Hay JH; Laskin JJ; Wu JS; Ho CC
    J Cancer Res Ther; 2013; 9(4):607-12. PubMed ID: 24518704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.
    Le Louedec F; Alix-Panabières C; Lafont T; Allal BC; Garrel R; Digue L; Guigay J; Cupissol D; Delord JP; Lallemant B; Alfonsi M; Aubry K; Mazel M; Becher F; Perriard F; Chatelut E; Thomas F
    Br J Clin Pharmacol; 2019 Jun; 85(6):1357-1366. PubMed ID: 30811063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study.
    Tiwari S; Goel V; John MC; Patnaik N; Doval DC
    Indian J Cancer; 2016; 53(4):487-492. PubMed ID: 28485336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
    Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
    Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.
    Bossi P; Kornek G; Lanzetta G; Rozzi A; Füreder T; Locati L; Licitra L
    Head Neck; 2013 Oct; 35(10):1471-4. PubMed ID: 23042567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
    Tinhofer I; Klinghammer K; Weichert W; Knödler M; Stenzinger A; Gauler T; Budach V; Keilholz U
    Clin Cancer Res; 2011 Aug; 17(15):5197-204. PubMed ID: 21653686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib in squamous cell carcinoma of the head and neck.
    Specenier P; Vermorken J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1295-301. PubMed ID: 27160335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of prophylactic percutaneous endoscopic gastrostomy tube placement on treatment tolerance in head and neck cancer patients treated with cetuximab plus radiation.
    Yamazaki T; Enokida T; Wakasugi T; Zenda S; Motegi A; Arahira S; Akimoto T; Tahara M
    Jpn J Clin Oncol; 2016 Sep; 46(9):825-31. PubMed ID: 27317736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous 5-Fluorouracil in Patients With Advanced Squamous Cell Carcinoma: A Retrospective Study.
    Buxó E; Sosa A; Reig O; Victoria I; Caballero M; Grau JJ; Garcia-Morillo M
    Ann Otol Rhinol Laryngol; 2018 Jul; 127(7):456-462. PubMed ID: 29852745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
    Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma.
    De Felice F; Vetrone L; Bulzonetti N; Caiazzo R; Marampon F; Musio D; Tombolini V
    Med Oncol; 2019 Jun; 36(8):68. PubMed ID: 31190132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
    Gilbert J; Schell MJ; Zhao X; Murphy B; Tanvetyanon T; Leon ME; Neil Hayes D; Haigentz M; Saba N; Nieva J; Bishop J; Sidransky D; Ravi R; Bedi A; Chung CH
    Oral Oncol; 2015 Apr; 51(4):376-82. PubMed ID: 25593015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma: experience from an area in which betel nut chewing is popular.
    Chang PM; Hsieh YY; Chen MH; Tzeng CH; Chu PY; Chang SY; Chen PM; Yang MH
    J Chin Med Assoc; 2010 Jun; 73(6):292-9. PubMed ID: 20603086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
    Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
    Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma.
    Fury MG; Xiao H; Sherman EJ; Baxi S; Smith-Marrone S; Schupak K; Gewanter R; Gelblum D; Haque S; Schoder H; Shah JP; Katabi N; Kurtzman R; Lipson B; Cox L; Lee NY; Pfister DG
    Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E566-70. PubMed ID: 25784616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients.
    Lobet S; Paintaud G; Azzopardi N; Passot C; Caulet M; Chautard R; Desvignes C; Capitain O; Tougeron D; Lecomte T; Ternant D
    Clin Pharmacokinet; 2023 Sep; 62(9):1263-1274. PubMed ID: 37442917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.